Global regulatory frameworksespecially the ICH S1 series guidelinesrequire structured carcinogenicity assessment: ICH S1A/S1B/S1C define when lifetime rodent studies are required Emphasis on hazard identification rather than direct human prediction Adoption of Weight-of-Evidence (WoE) approaches in ICH S1B(R1) The updated S1B(R1) guideline specifically encourages: Integration of mechanistic, exposure, and translational data Reduced reliance on 2-year rodent bioassays when justified Greater emphasis on human relevance and multi-factor evidence This shift reflects a broader regulatory evolution toward mechanism-based safety assessment rather than purely animal-driven hazard signals
Bowling Green was even dubbed Ozempictown, USA given how many prescriptions were filed in the state of Kentucky
While not typically covered for general weight loss, some argue that short-term use in specific casessuch as preparing a patient for surgerymight be justified
Filingeri noted that this research study was designed to further examine changes in weight, body fat mass, and muscle mass in patients taking incretin medications. We found that, under close supervision and regular follow-up from an obesity medicine specialist, patients were able to lose fat mass with only a minimal decline in muscle mass. Alexandra Filingeri, DCN, RCN Filingeri pointed out that the results of this study cannot be generalized to patients receiving medication via telemedicine without routine body composition analysis, nor can they be generalized to in-person visits without utilizing body composition analysis
